PTC Shares Update on Regulatory Processes for Translarna in Europe and United States

December 15, 2023

On December 14, 2023, PTC Therapeutics shared an update to the Duchenne community about current regulatory processes for Translarna (ataluren) in Europe and the United States.

Please click here to view PTC’s letter.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open